Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. (November 2017)

• Record Type: Journal Article
• Authors: Davidson, Jaime; Kalra, Sanjay; Singh, Vikram; Fegade, Mayuresh; Singh, Gursimran; Mane, Amey
• Is Part Of: Diabetes & metabolic syndrome. Volume 11(2017)Supplement 1
• Page Start: S159
• Page End: S168
• Publication Date: 2017-11
• Subjects: Canagliflozin -- Dapagliflozin -- Empagliflozin -- KgA1c paradox -- Overweight -- SGLT2 inhibitors -- Type 2 diabetes mellitus; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; Diabetes Mellitus -- Periodicals; Metabolic Diseases -- Periodicals; Diabète -- Périodiques; Métabolisme, Troubles du -- Périodiques; Endocrinologie -- Périodiques; Diabète -- Physiopathologie -- Périodiques; Diabetes; Metabolism -- Disorders; Electronic journals; Periodicals; 616.462
• DOI: 10.1016/j.dsx.2016.12.026
• Languages: English
• ISSNs: 1871-4021

Abstract

Abstract: Excess body weight is a leading cause of metabolic complications such as hypertension and dyslipidemia in T2DM patients. Available antihyperglycemic agents have minimal or no impact on these complications and a majority are known to trigger weight gain, thereby exerting a paradoxical effect on overall metabolic status. This review introduces the concept of 'KgA1c paradox' and underscores the significance of resolving this paradox for comprehensive T2DM management. It provides a therapeutic rationale for inclusion of sodium glucose cotransporter 2 inhibitors in the T2DM treatment algorithm as these agents have demonstrated favorable glycemic effects along with reduction in body weight.